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Abstract
Background: Cats with subclinical hypertrophic cardiomyopathy (sHCM) have ele-
vated serum insulin and serum amyloid A concentrations correlating with the degree
of cardiac hypertrophy. Diet might affect these and other cardiac variables.
Objective: Evaluate the effect of a complete, balanced diet with restricted starch and
supplemented with eicosapentaenoic acid + docosahexaenoic acid (EPA + DHA) on
echocardiographic variables and cardiac biomarkers in cats with sHCM.
Animals: Forty-four client-owned cats with sHCM.
Methods: A prospective, randomized, double-blind, multicenter study enrolled cats
with end-diastole interventricular septum thickness (IVSd) or left ventricular wall
thickness (LVWd) ≥6 mm, or both. Nonsedated, fasted cats were examined at base-
line and after 6 and 12 months of Test (restricted starch and EPA + DHA supple-
ments) (n = 23) or Control (unrestricted starch without EPA + DHA supplementation)
(n = 21) diet. Assessments included auscultation, body weight, body condition score,
echocardiography and blood analysis. Linear and generalized mixed models analyzed
diet, time and diet * time interactions (5% significance level).
Abbreviations: 2D, 2-dimensional; Ao, aorta; BCS, body condition score; BW, body weight; CHF, congestive heart failure; cTnI, cardiac troponin I; CV, coefficient of variation; DHA,
docosahexaenoic acid; DLVOTO, dynamic left ventricular outflow tract obstruction; EPA, eicosapentaenoic acid; HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic obstructive
cardiomyopathy; HR, heart rate; IGF-1, insulin-like growth factor-1; IVS, interventricular septum; IVSd, end-diastolic interventricular septum thickness; LA, left atrium/atrial; LA/Ao, ratio of the
left atrial dimension to the aortic annulus dimension; LV, left ventricle/ventricular; LVFW, left ventricular free wall; LVH, left ventricular hypertrophy; LVIDd, left ventricular internal dimension at
end-diastole; LVIDs, left ventricular internal dimension at end-systole; LVOT, left ventricular outflow tract; LVWd, end-diastolic left ventricular free wall thickness; ME, metabolizable energy;
NFE, nitrogen-free extract; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RVOT/PA, right ventricular outflow tract/pulmonary artery; SAA, serum amyloid A; sHCM, subclinical
hypertrophic cardiomyopathy; T4, total thyroxine.
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Results: No differences between diet groups were significant for any variable at any
timepoint. There were significant decreases in the Test but not Control group in max-
imum IVSd (P = .03), maximum LVWd (P = .02) and insulin-like growth factor-1 levels
(P = .04) after 12 months, and in ultrasensitive cardiac troponin I (cTnI) (P = .001) after
6 months; effect sizes (95% confidence interval) were 0.53 (0.09; 0.99), 0.63 (0.18;
1.09), 0.61 (0.16; 1.07), and 0.37 (−0.06; 0.8), respectively.
Conclusions and Clinical Importance: Cats with sHCM fed Test diet had significant
decreases in echocardiographic variables of sHCM and in cTnI and IGF-1.
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1 | INTRODUCTION
Subclinical hypertrophic cardiomyopathy (sHCM) has a prevalence of
15% in apparently healthy cats.1,2 Medication of cats with sHCM
remains controversial, as there is no proof of efficacy of any treat-
ment. Drug treatment is based on extrapolation from human trials,
experimental research models, anecdotes and personal opinions.3 Cur-
rent therapy targets clinical markers of cardiovascular risk and morbid-
ity, and any effect on disease progression, morbidity or outcome
remains unclear due to the absence of clinical trials.4
In humans, insulin plays an important role in cardiac hypertrophy
through Akt-signaling pathways, stimulating protein synthesis and
inhibiting protein breakdown in cardiomyocytes, and causing ventric-
ular hypertrophy.5 These effects are enhanced by insulin-like growth
factor-1 (IGF-1), as insulin and IGF-1 can both activate each other's
receptor, albeit with reduced affinity compared with their own recep-
tors.6 Hypertrophic cardiomyopathy (HCM) in cats has genotypical
and phenotypical similarities to HCM in humans, although the dis-
ease is more severe and progresses more quickly in some cats.7 Insu-
lin, IGF-1 and inflammation are implicated in cats with sHCM.8
Serum insulin concentrations are significantly higher than the labora-
tory reference range in cats with sHCM.8 Serum amyloid A (SAA)
levels are significantly higher in cats with generalized hypertrophy
compared to cats with focal or multifocal hypertrophy, and are signif-
icantly correlated with the number of hypertrophied regions in the
interventricular septum (IVS) (ρ = .28, P = .05).8 In humans, circulating
concentrations of IGF-1 are higher in patients with HCM compared
with controls,9 regional expression of IGF-1 in the myocardium is
elevated,10 and inflammation plays a role in the pathophysiology of
heart failure.11 As in humans with HCM, exogenous modulation of
the insulin/IGF-1 axis and myocardial inflammation might be benefi-
cial in the management of cardiovascular disease with increased
myocardial mass in cats.11,12
Dietary digestible carbohydrates greatly influence the availability
of insulin to the heart, and might therefore play a role in car-
diomyocyte growth.13 Omega-3 fatty acids might have effects on car-
diac structure and function through their anti-inflammatory actions, as
well as leading to a decrease in protein synthesis and to remodeling of
hypertrophic cardiomyocytes.14-17
We hypothesized that dietary starch and omega-3 fatty acids
influence cardiomyocyte hypertrophy and therefore thickness of the
IVS and left ventricular free wall (LVFW). The objective of this study
was to evaluate a complete diet with restricted starch and sup-
plemented with eicosapentanoic acid + docosahexaenoic acid (EPA
+ DHA) for its effect on echocardiographic measurements and cardiac
biomarkers in cats with sHCM.
2 | MATERIALS AND METHODS
2.1 | Study design
We performed a prospective randomized, double-blind, multicenter
study to evaluate the effects of diet on clinical, biochemical and echo-
cardiographic variables in cats with sHCM.
Adult cats from 8 months of age were recruited from 4 centers in
the United Kingdom (A-D). Cats were enrolled with the informed consent
of owners and ethical approval was obtained from the Royal Canin Ethics
Committee, Institution A Committee on Research Ethics (VREC335) and
Institution C Committee on Research Ethics (VERC 93.16).
To be eligible, cats had to be diagnosed with HCM on echocardiogra-
phy and have no clinical signs of heart disease (International Small Animal
Cardiac Health Council stage 1b).19 Hypertrophic cardiomyopathy was
diagnosed when the greatest IVS thickness at end-diastole (IVSd), or
LVFWwall thickness at end-diastole (LVWd), or both measured ≥6 mm on
M-dimensional or 2-dimensional (2D)-mode.20 Additional findings consis-
tent with HCM in some cats included systolic anterior motion of the mitral
valve, dynamic LV outflow tract obstruction or left atrial enlargement.
Exclusion criteria included important concurrent systemic disease
based on history, physical examination and laboratory testing (biochemis-
try profile and total thyroxine [T4]). Cardiac medications were allowed if
they had been administered for at least 8 weeks before study start. If car-
diac medication was clinically necessary after initial diagnosis of HCM,
study entry was postponed for a minimum of 8 weeks.
2198 VAN HOEK ET AL.
All assessments were performed at baseline before dietary interven-
tion, and at 6 and 12 months after the initiation of study diets. Physical
examinations, body condition score (BCS on a 9-point scale21), blood
pressure measurement and echocardiography were performed by a board-
certified cardiologist or a board-eligible cardiologist supervised by a board-
certified cardiologist. Blood pressure was measured by Doppler technique.
The mean was taken from 3 systolic values that were within 10% of each
other, selected from at least 5 serial measurements taken after acclimatiza-
tion of the cat. Cats with a systolic blood pressure >180 mmHg were con-
sidered hypertensive and excluded from the study.22
2.2 | Echocardiography
Echocardiography (2D, M-mode and color flow, spectral, and tissue
Doppler) was performed on all cats in the conscious state without
chemical restraint, scanned from beneath in lateral recumbency on a
purpose-designed table. A 7.5 to 12 MHz transducer was used to per-
form transthoracic echocardiography as recommended for cats by the
Echocardiography Committee of the Specialty of Cardiology.23 A mini-
mum of 3 and usually 5 measurements of each echocardiographic var-
iable were made, and the mean value determined and recorded.
Echocardiographic measurements were made off-line immediately
after echocardiography by the same investigator carrying out echocar-
diography. Values were uploaded into the study website on the same
day. All cats had a full echocardiographic assessment, including assess-
ment of diastolic function and estimation of left-side filling pressures,
but only the measurements detailed were assessed as part of this
study.
Right parasternal 4-chamber and 5-chamber long-axis and short-
axis views at papillary muscle, mitral valve and aortic valve levels were
taken. Left ventricular (LV), mitral valve, and left atrial/aortic M-modes
were obtained after cursor placement guided by 2D images. M-mode
measurements used leading-edge to leading-edge methodology. Two-
dimensional measurements of the IVS, LV cavity and LVFW at the end
of diastole and systole were made on the short-axis view at papillary
muscle level, using blood-endocardial and myocardial-epicardial inter-
faces to guide caliper placement. Two-dimensional left atrial and aor-
tic measurements were obtained from the right parasternal short-axis
view at the end of diastole (start of QRS complex) when endocardial
borders could be reliably visualized. Two-dimensional IVS and LVFW
measurements were taken from the right parasternal short-axis and
long-axis (4-chamber or 5-chamber) view of the LV at the end of dias-
tole.22 Interventricular septum in diastole was measured in basal, mid
and apical regions; LVWd was measured in basal and mid regions from
right parasternal long-axis 4-chamber or 5-chamber views, whichever
optimized any focal hypertrophy. Papillary muscles and any false ten-
dons were excluded from these measurements. All values were
recorded as maximum thickness (max-), the sum of thicknesses mea-
sured in the 5 separate regions (sum-), and the number of regions with
≥6 mm thickness (n-). Generalized hypertrophy was defined as thick-
ness ≥6 mm in all 5 regions of both IVSd and LVWd. Left atrial
(LA) enlargement was defined as LA max ≥16 mm,24 or short axis end-
diastolic ratio of the left atrial dimension to the aortic annulus dimen-
sion (LA/Ao) ≥1.5, or both.25
Heart rate was calculated as 60 000/R-R interval (in milliseconds)
from an average of 3 cardiac cycles in sinus rhythm, measured toward
the end of right-sided echocardiography, after the cat had acclima-
tized. If contemporaneous electrocardiogram data were not available
for heart rate, the rate counted during auscultation was used.
Left apical 5-chamber views were obtained for spectral Doppler
assessments of LV outflow tract (LVOT) and aortic flow. Cranial right
and left parasternal views optimizing right ventricular outflow tract/
pulmonary artery (RVOT/PA) flow were obtained for spectral Doppler
from these regions; measurements were made from the images which
best optimized these. Velocities of LVOT, aortic and RVOT and pul-
monic flow were taken from pulsed-wave envelopes (or continuous
wave if aliasing was evident) in spectral Doppler recordings. In order
to assist with clinical staging and prognostication for individual cats
(not part of this study), diastolic function and left-sided filling pres-
sures were evaluated,26,27 facilitated by vagal maneuvers if
required.28
Echocardiographic measures on stored images of LA, IVSd and
LVWd from 13 cats and 4 observers from site A, and from 6 cats and
2 observers from site B were analyzed to estimate coefficients of vari-
ation (CV).
Three categories of CV were analyzed: intraobserver intracenter
CV, interobserver intracenter CV, and interobserver intercenter
CV. The entire echocardiographic study was provided for the second
or third observer (interobserver CV) for additional measurements, so
each observer could select which cine loops or images were appropri-
ate for measurement (ie, the same stored image or loop or cardiac
cycle was not necessarily remeasured for this part of the study).
2.3 | Blood analysis
Blood was collected by cephalic or jugular venipuncture into serum
tubes after an overnight fast. Samples were divided into 3 aliquots,
frozen at −20C and shipped the same day to Idexx Bioanalytics,
Germany. One aliquot was thawed on the day of arrival for analysis of
biochemistry (Beckman Coulter AU58000, Beckman Coulter, Brea
CA), total T4 (DRI Thyroxine, Microgenics, Fremont, California), car-
diac troponin I (cTnI) (ADVIA Centaur TnI-Ultra Assay, Siemens
Healthineers, Germany), glucose (Immulite 2000/XPi, Siemens
Healthineers, Germany), IGF-1 (CLIA, Siemens, Immulite 2000, Idexx,
Germany) and SAA (LAA, Eiken Chemical, Beckman Coulter AU5800,
Idexx, Germany). One aliquot was kept frozen at −80C and shipped
on dry ice to the UK for analysis of insulin (IRMA, Beckman Coulter,
Nationwide, UK) within approximately 8 days after blood collection.
The remaining aliquot was thawed on the day of arrival or frozen at
−80C and thawed within 2 days for analysis of N-terminal pro B-type
natriuretic peptide (NT-proBNP) (Feline Cardiopet NT-proBNP Immu-
noassay, Idexx, Germany).
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2.4 | Dietary intervention
Cats were allocated to 1 of 2 coded diets (Test and Control) by a
computer-based random number generator during verification of eligi-
bility. Cardiologists, technicians, owners, and investigators were
blinded to diet allocations until the final study results were analyzed
and interpreted. The only investigator aware of the diet assignment
was not involved in cat enrollment. There was a dry and moist format
option for each diet; owners could opt for feeding 1 or a mixture of
formats according to the cat's preference.
Both diets were mildly sodium-restricted (<0.7 g/MCal) and were
complete and balanced (ie, sufficient to supply all nutrient require-
ments). Dry and moist formats for each diet had similar nutrient pro-
files. The main differences between Test diet and Control diet were
the levels of nitrogen-free extract (% dry matter − [% protein + % fat
+ % crude fiber + % ash]), starch, protein, and EPA + DHA (Table 1).
The Test diet was restricted in starch, higher in protein than the Con-
trol diet and supplemented with EPA + DHA. Diet rationing was based
on recommended energy intake for the BCS of each cat (BCS 1-
5: 78 kcal/kg bodyweight [BW]0.71; BCS 6-9: 62 kcal/kg BW0.71).
Owners were instructed to feed study diet exclusively without addi-
tion of treats, table scraps or other food. If cats showed signs that
intake was too low or too high, intake was adjusted to give 10%
energy increase or decrease, respectively. Baseline assessments were
repeated after 6 months and 12 months of feeding study diet.
2.5 | Statistical analysis
Primary endpoints were IVSd and LVWd. Secondary endpoints were
LA dimension and IGF-1, insulin, NT-proBNP, and cTnI concentra-
tions. Power analysis estimated that a total sample size of between
40 and 100 cases was required to detect a medium to large effect of
diet.29,30 All data were analyzed using the Statistical Analysis Systems
Institute package (SAS version 9.4; SAS Institute Inc.). Data are
expressed as median and range (minimum-maximum) unless stated
otherwise.
Differences between diet groups at baseline were analyzed
using unpaired t tests for continuous variables (age, BW, and BCS),
and chi-squared tests for nominal variables (sex, medication, breeds,
site, diet format, and murmur). Linear mixed models (2-way
repeated-measures ANOVA comparing measured variables with
visit time and group) were used for continuous variables, and gener-
alized linear mixed models for nominal variables. Time, diet and the
interaction between them were defined as fixed effects; cat was a
random term. Site effect was removed from the analysis after it was
shown not to have a significant effect. For linear mixed models, data
were log or rank transformed if needed in order to fulfill model
assumptions (normally distributed residuals and homoscedasticity).
Multiple pair-wise post hoc comparisons were made for those fixed
effects that were significant, and these comparisons were adjusted
using Tukey honest significant difference to avoid alpha risk
inflation.
Between timepoints within diet groups Cohen's d effect size for
continuous variables and odds ratio for discrete variables were calcu-
lated with their associated 95% CI.
The level of statistical significance was set at P < .05, for all
2-sided analyses.
Three categories of CV (intraobserver intracenter CV, inter-
observer intracenter CV, and interobserver intercenter CV) were cal-
culated with each set of observations for the corresponding category
of CV ([SD/mean] * 100).
3 | RESULTS
3.1 | Study group
Between November 2015 and June 2017, 55 cats were screened for
enrollment, 51 cats were eligible and received their allocated diet and
44 completed the study (Figure 1). One cat in the Test group died
suddenly following vaccination 4 months after study start; it was
assumed to have had acute cardiac failure. There were 2 deaths in the
Control group: 1 at 8 months and 1 at 6 months after study start due
to chronic heart failure and unknown cause, respectively. Results are
presented for the 44 cats that completed the study. The Test group
consisted of 23 cats (dry diet n = 10, moist diet n = 2 and mixed dry
and moist diet n = 11) and the Control group consisted of 21 cats (dry
diet n = 4, moist diet n = 2 and mixed dry and moist n = 15) (Table 2).
Cats ate the same diet formats throughout the study. Over the
12-month study period, there were no reports of diet refusal or chan-
ged eating behavior, and BW or BCS did not significantly change
(Table 3).
There were no significant differences at baseline between Test
and Control group in signalment (Table 2), clinical characteristics
(Table 2), medical center distribution (Table 2), biochemical variables
(Table 3), or echocardiographic measurements (Table 4). The median
age across groups was 5 (range, 1.4-17) years. Most cats (70%) were
TABLE 1 Composition of Test and Control diets
Test diet Control diet
Dry Moist Dry Moist
Moisture (%) 5.5 80 5.5 79
Protein (g/MCal) 125 133.6 63.6 113.4
Fat (g/MCal) 34.8 41.3 36.8 38.5
EPA + DHA (g/MCal) 0.6 1.8 0.019 0.05
Starch (g/MCal) 38.8 19.4 113.4 46.5
NFE (g/MCal) 57.3 32.2 117.9 59.5
Sodium (g/MCal) 0.68 0.6 0.64 0.6
ME (kcal/kg) 3765 383 3955 392
Abbreviations: DHA, docosahexaenoic acid; DM, dry matter; EPA,
eicosapentaenioc acid; ME, metabolizable energy; NFE, nitrogen-free
extract.
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male. Forty-two cats (95.5%) had a murmur and this was grade ≥3 in
28 (63.6%) cats. Median (range) blood pressure was 130 (92-165)
mm Hg at baseline, 130 (94-162) mm Hg after 6 months, and
122 (96-180) mm Hg after 12 months.
Eight cats received medications (atenolol with or without
clopidogrel or telmisartan) (Table 2). No cats initiated medication dur-
ing the study and no cats on medication at baseline stopped
medication.
3.2 | Primary and secondary endpoints
There was a significant diet * time interaction for both IGF-1 (P = .02)
and heart rate (P = .02). IGF-1 significantly decreased between base-
line and 12 months in the Test group compared with no difference in
the Control group (effect size [95% CI] 0.61 [0.16; 1.07] vs −1 [−0.54;
0.33]) (Table 4, Figure 2). Heart rate significantly decreased between
baseline and 12 months in the Test group (P = .005), but was not sig-
nificantly different between the 2 groups at 12 months (effect size
[95% CI] 0.65 [0.19; 1.13] for the Test group and 0.31 [−0.14; 0.76]
for the Control group) (Table 4).
Several other variables significantly changed over time in the
Test group but not in the Control group; however no differences
between the diet groups were significant for any variable at any
timepoint. There was a significant effect of time for primary end-
points max-IVSd (P = .004), max-LVWd (P = .004), n-IVSd
(P < .001) and sum-IVSd (P < .001) (Figure 2). All of these variables
were significantly decreased at 12 months in the Test group but
not the Control group. Effect sizes (95% CI) between baseline and
12 months were higher for the Test group compared with the Con-
trol group: 0.53 (0.09; 0.99) vs 0.36 (−0.09; 0.82) for max-IVSd,
0.63 (0.18; 1.09) vs 0.22 (−0.22; 0.67) for max-LVWd, 0.86 (0.38;
1.36) vs 0.44 (−0.02; 0.9) for n-IVSd and 0.87 (0.39; 1.38) vs 0.58
(0.12; 1.07) for sum-IVSd. Median max-LVWd decreased in the
Test group after 12 months to values below cut-off level of 6 mm
(Table 4).
Secondary endpoints and other variables are described in Tables 3
and 4. In the Test group, cTnI decreased significantly between base-
line and 6 months but not 12 months (effect size [95% CI] 0.37
(−0.06; 0.8) and 0.33 (−0.1; 0.76), respectively), compared with no sig-
nificant change in the Control group at either timepoint (Table 3,
Figure 2). Although there were no significant differences between diet
groups, normalization of both max-IVSd and max-LVWd (≤6 mm wall
thickness) occurred after 12 months of diet in 30% of cats in Test
group and 14% of cats in Control group.
3.3 | Subpopulations
To evaluate the effect of the diet in cats with more or less advanced
sHCM, a subanalysis was conducted on cats with and without LA
enlargement.
In cats without LA enlargement, there was a significant effect
of time and a significant decrease between baseline and 12 months
in the Test group for n-IVSd, sum-IVSd, max-LVWd, LA-max, and
heart rate (Table 5). Time also had a significant effect on max-IVSd,
sum-LVWd, n-(IVSd + LVWd), and cTnI, but decreases in these
values at 12 months were not significant in either diet group
(Table 5).
In cats with LA enlargement, the effect of time on n-IVSd and
sum-IVSd was significant, as was the decrease in these variables
between baseline and 12 months in the Test group. There was a time
effect for n-(IVSd + LVWd), max-LVOT, max-RVOT, and cTnI, without
significant changes in these variables from baseline to 12 months
(Table 5). However, in the Test group but not the Control group there
were significant decreases at 6 months in max-LVOT (P = .02 and
P = .98, respectively) and cTnI (P = .03 and P = .99, respectively), with
effect sizes (95% CI) of 0.86 (0.21; 1.55) for max-LVOT and 0.41
(−0.17; 1.01) for cTnI.
F IGURE 1 Consolidated Standards of Reporting Trials
(CONSORT) flow diagram18 detailing the number of cats that were
randomized and assessed for eligibility, that were allocated a diet
and that completed the 12 month dietary intervention. For practical
reasons, cats were allocated to 1 of 2 diet groups by a computer-
based random number generator during verification of eligibility.
After ensuring eligibility, cats were enrolled and received the
allocated diet
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3.4 | Intraobserver and interobserver variability
There were 3 categories of CV: intraobserver intracenter CV ranging
from 3.2% to 5.2%, interobserver intracenter CV ranging from 3.7% to
10.7%, and interobserver intercenter CV ranging from 4.2% to 18.9%
(Table 6). Intraobserver and interobserver CV for primary endpoints
max-IVSd and max-LVWd were ≤5.9%.
4 | DISCUSSION
The results of this study support for the first time an effect of diet on
echocardiographic variables in cats with sHCM. Cats fed Test diet for
12 months had significantly decreased thickness of IVSd and LVWd,
with the latter measurements being comparable to healthy cats. There
were also significant reductions in cTnI and IGF-1, with the latter
interacting significantly with diet. These findings are consistent with a
previous study in which insulin, IGF-1 metabolism and inflammation
were identified as possible contributors to the mechanism modulating
sHCM.8 The Test diet was formulated with the objective of minimiz-
ing basal and peak insulin concentrations in the blood, and it was sup-
plemented with fish oil, known for its anti-inflammatory properties.
Exposure of the heart to insulin and IGF-1 is mainly determined by
dietary intake of digestible carbohydrates.13 Low carbohydrate diets
have proven effectiveness in improving cardiac remodeling and func-
tion in humans and rats.13,31,32
Despite significant changes from baseline in primary and sec-
ondary endpoints in the Test group, the lack of significant
TABLE 2 Baseline demographics,
clinical characteristics, diet format, and
center distribution of study cats with
subclinical hypertrophic cardiomyopathy
Variable Test group (n = 23) Control group (n = 21) P value
Age (years) 4.3 (1.42-17) 7.9 (2-13.9) .47
Sex .6
Male 17 14
Female 6 7
Body weight (kg) 5.0 (2.9-8.7) 4.8 (3.2-7.5) .7
Body condition score (1-9) 5 (3-9) 5 (4-7) .55
Medications (n) 2 6 .08
Atenolol 2 3
Atenolol and telmisartan 0 1
Atenolol and clopidogrel 0 2
Breeds (n) .06
DSH + DLH 19 12
British Shorthair 0 3
Selkirk Rex 1 2
Persian 1 1
Ragdoll cross 1 1
Exotic shorthair 1 0
Siamese 0 1
Maine Coon 0 1
Centers (n) .83
A 12 12
B 9 8
C 1 1
D 1 0
Diet format (n) .2
Dry only 10 4
Wet only 2 2
Mixed 11 15
Heart murmur (n) 23 19 .14
Grade 1-2 6 8
Grade ≥ 3 17 11
Note: Data are presented as median and range (minimum-maximum).
Abbreviations: DLH, domestic long-hair; DSH, domestic short-hair.
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difference between the diets at any timepoint for any variable,
limits clinical interpretation of the findings. The absence of statisti-
cal differences between diets with respect to IVSd and LVWd
might be explained by the fact that these variables declined non-
significantly in the Control group as well as declining significantly
in the Test group, although the effect sizes were larger in the
Test group.
There was a significant diet * time interaction for IGF-1, and
IGF-1 also decreased significantly with regression of IVSd and
LVWd hypertrophy over 12 months in cats fed Test diet. Cats with
hypersomatotropism frequently have ventricular hypertrophy.33,34
Our findings are comparable with the reversible effect of hypophy-
sectomy on cardiac hypertrophy and the concurrent decrease in
circulating IGF-1 in cats with hypersomatotropism.35 However, the
main effect of diet on insulin/IGF-1 metabolism was decreased
IGF-1 and there was no effect on insulin concentrations. This is
surprising, considering that cats with sHCM have insulin concen-
trations elevated above the laboratory reference range,8 similar to
those reported in humans.36,37 Possibly a relatively high protein
and amino acid content in our Test diet prevented a reduction in
insulin secretion.38 It is also possible that the overnight fasting
before blood sampling was too short for decreases in basal insulin
concentrations to be observed. In rats, the hypertrophic response
of cardiac myocytes to insulin is greater than that to IGF-1.39 Our
data suggest that in cats, reversal of cardiac hypertrophy can occur
with decreases in IGF-1 levels without concurrent decreases in
insulin levels.
There was also a similar significant diet * time interaction for
heart rate, which decreased over time, but only in the Test diet group.
This observation remains unexplained—if it reflected acclimatization
of cats to study procedures the same effect would be expected in the
Control group. It is unlikely that heart rate reduction affected the pri-
mary endpoints of diastolic wall thickness or LA dimension, especially
as there was no significant difference in heart rate between groups at
each time point and the rate reduction in the Test group was minor
(median reduction 4 bpm). Although heart rate (R-R interval) can influ-
ence variables associated with diastolic function27 and systolic func-
tion, no major effect on LVFW thickness or left atrial size is
expected26 or has been reported in cats with sHCM.40 In anesthetized
healthy cats, there is a significant correlation between diastolic wall
thickness and heart rate when atrial pacing is used to manipulate
heart rate.41 Whether the converse is true in this study with
unsedated cats with physiological heart rates is unclear.
We also investigated the effect of omega-3 fatty acids on the
inflammatory marker SAA. Omega-3 fatty acids have beneficial
effects in cardiovascular disease, for managing arrhythmias, but also
myocardial energy metabolism, endothelial and immune function,
heart rate, and blood pressure.17 With respect to cardiac remo-
deling, in vitro EPA + DHA treatment of rat hypertrophic
cardiomyocytes decreases protein synthesis, cell surface area, atrial
natriuretic peptide levels and remodeling.15,16,42 A previous study
showed that SAA levels were not significantly higher than the labo-
ratory reference range in cats with sHCM, although they were
higher in cats with generalized hypertrophy compared to focal or
TABLE 3 Body weight, body condition score, and laboratory measurements in cats with subclinical hypertrophic cardiomyopathy randomized
to Test or Control diet for 12 months
Test group (n = 23) Control group (n = 21)
Baseline 6 months 12 months Baseline 6 months 12 months
BW (kg) 5.0 (2.9-8.7) 4.9 (2.7-7.9) 4.9 (2.7-7.7) 4.8 (3.2-7.5) 4.9 (3.28-7.8) 4.9 (3.2-7.4)
Effect size (95% CI) 0.09 (−0.33; 0.51) 0.28 (−0.14; 0.71) 0.11 (−0.33; 0.55) 0.21 (−0.23; 0.66)
BCS (1-9) 5 (3-9) 6 (2-8) 6 (2-7) 5 (4-7) 5 (3-8) 5 (3-7)
Effect size (95% CI) −0.06 (−0.48; 0.36) 0.15 (−0.27; 0.57) 0.06 (−0.38; 0.5) 0.15 (−0.29; 0.59)
Insulin (μU/mL) 24 (8.9-113) 32.5 (6.6-58) 42 (6.3-70) 16.7 (3.9-76) 24.2 (7.4-123) 16.8 (6.2-129)
Effect size (95% CI) −0.33 (−0.76; 0.1) −0.49 (−0.94; −0.05) −0.36 (−0.82; 0.09) −0.18 (−0.63; 0.26)
IGF-1 (ng/mL) 460 (216-772) 369 (118-658) 401 (73.3-720)a 448 (207-786) 463 (66.5-956) 498 (132-1000)
Effect size (95% CI) 0.88 (0.4; 1.38) 0.61 (0.16; 1.07) −0.05 (−0.49; 0.39) −0.1 (−0.54; 0.33)
SAA (mg/L) 0 (0-1.5) 0 (0-34.5) 0 (0-1.3) 0.0 (0.0-21.8) 0.05 (0-12.4) 0 (0-34)
Odds ratio (95% CI) 1.00 (0.26; 3.81) 0.43 (0.08; 1.87) 2.20 (0.64; 7.96) 1.23 (0.35; 4.46)
NT-proBNP (pmol/L) 211 (24-1500) 98 (24-1500) 150 (26-1500) 271 (26-1500) 199.5 (24-1500) 263 (24-1500)
Effect size (95% CI) 0.14 (−0.28; 0.56) −0.11 (−0.53; 0.31) −0.09 (−0.53; 0.35) −0.39 (−0.85; 0.06)
cTnI (ng/mL) 0.16 (0.02-9.49) 0.07 (0.01-0.55)b 0.12 (0.01-.56) 0.14 (0.01-1.74) 0.1 (0.01-2.25) 0.1 (0.01-2.35)
Effect size (95% CI) 0.37 (−0.06; 0.8) 0.33 (−0.1; 0.76) 0.02 (−0.41; 0.46) −0.23 (−0.68; 0.21)
Note: Data are presented as median and range (minimum-maximum). There was no significant difference between diet groups at baseline. Text in bold
indicates statistically significant differences for other timepoints compared with baseline.
Abbreviations: CI, confidence interval; BCS, body condition score; BW, bodyweight; cTNI, cardic troponin I; IGF-1, insulin-like growth factor-1; NT-
proBNP, N-terminal pro B-type natriuretic peptide; SAA, serum amyloid A.
aP = .04 and bP = .001 for the comparisons with baseline of the Test group. Effect sizes (Cohen's d) between baseline and the stated timepoint are given
for each variable within each diet group; SAA was analyzed as discrete (nominal) data and therefore odds ratios are shown instead.
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TABLE 4 Echocardiographic measurements in cats with subclinical hypertrophic cardiomyopathy randomized to Test or Control diet for
12 months
Test group (n = 23) Control group (n = 21)
Baseline 6 months 12 months Baseline 6 months 12 months
Heart rate (bpm) 169 (140-240) NA 165 (101-187)a 171 (118-220) NA 165 (131-204)
Effect size (95% CI) 0.65 (0.19; 1.13) 0.31 (−0.14; 0.76)
2D assessments (mm)
Max-IVSd 6.97 (5.50-8.70) 6.50 (5.00-7.90) 6.30 (3.93-9.00)a,b 7.30 (5.90-9.20) 6.80 (5.40-8.90) 6.70 (4.30-9.90)
Effect size (95% CI) 0.34 (−0.09; 0.77) 0.53 (0.09; 0.99) 0.4 (−0.05; 0.86) 0.36 (−0.09; 0.82)
n-IVSd 2.0 (0.0-3.0) 2.0 (0.0-3.0) 1.0 (0.0-3.0)a,b,c,d 2.0 (0.0-3.0) 2.0 (0.0-3.0) 2.0 (0.0-3.0)
Effect size (95% CI) 0.32 (−0.1; 0.76) 0.86 (0.38; 1.36) 0.05 (−0.39; 0.49) 0.44 (−0.02; 0.9)
Sum-IVSd 18.80 (14.40-22.50) 18.30 (13.10-21.30) 16.50 (11.00-21.20)a,b 18.80 (15.60-23.50) 19.10 (13.90-24.00) 17.70 (12.60-26.10)
Effect size (95% CI) 0.6 (0.15; 1.06) 0.87 (0.39; 1.38) 0.39 (−0.06; 0.85) 0.58 (0.12; 1.07)
Max-LVWd 6.10 (4.10-8.00) 5.60 (3.30-7.50)e 5.30 (4.08-7.20)a 6.60 (4.40-7.80) 6.10 (3.50-9.00) 6.30 (4.00-8.00)
Effect size (95% CI) 0.89 (0.41; 1.4) 0.63 (0.18; 1.09) 0.28 (−0.17; 0.73) 0.22 (−0.22; 0.67)
n-LVWd 1.0 (0.0-2.0) 0 (0.0-2.0) 0 (0.0-2.0) 1.0 (0.0-2.0) 1.0 (0.0-2.0) 1.0 (0.0-2.0)
Odds ratio (95% CI) 0.23 (0.06; 0.76) 0.41 (0.12; 1.33) 0.67 (0.19; 2.33) 0.81 (0.22; 2.89)
Sum-LVWd 11.80 (7.60-15.20) 10.70 (6.40-14.60) 10.30 (6.86-14.40) 12.11 (8.50-15.00) 11.50 (6.80-17.90) 11.70 (7.90-15.50)
Effect size (95% CI) 0.7 (0.24; 1.18) 0.54 (0.09; 0.99) 0.29 (−0.15; 0.74) 0.2 (−0.24; 0.64)
n-(IVSd + LVWd) 3.0 (1.0-5.0) 2.0 (0.0-5.0) 1.0 (0.0-5.0) 3.0 (0.0-5.0) 3.0 (0.0-5.0) 3.0 (0.0-5.0)
Effect size (95% CI) 0.53 (0.09; 0.99) 0.68 (0.23; 1.16) 0.3 (−0.14; 0.75) 0.38 (−0.07; 0.84)
LVIDs 7.40 (3.10-10.40) 7.20 (1.80-10.80) 7.70 (1.70-11.00) 7.60 (3.00-12.00) 7.50 (2.30-10.40) 6.70 (3.20-14.00)
Effect size (95% CI) 0.01 (−0.41; 0.43) −0.19 (−0.62; 0.23) 0.18 (−0.26; 0.63) 0.3 (−0.15; 0.75)
LVIDd 14.30 (9.20-17.30) 14.30 (11.40-18.10) 15.70 (12.2-19.30) 14.20 (1.27-20.00) 14.70 (10.00-18.39) 14.10 (10.30-20.00)
Effect size (95% CI) −0.16 (−0.59; 0.25) −0.35 (−0.78; 0.08) −0.41 (−0.87; 0.04) −0.31 (−0.77; 0.13)
LA-max 15.30 (11.40-20.00) 15.40 (12.10-19.50) 16.30 (11.65-24.9) 16.00 (12.20-23.40) 16.41 (11.30-24.00) 15.50 (12.20-32.30)
Effect size (95% CI) −0.24 (−0.66; 0.18) −0.4 (−0.84; 0.03) −0.26 (−0.71; 0.18) −0.33 (−0.79; 0.11)
LA/Ao 1.27 (0.97-1.70) 1.30 (1.00-1.50) 1.30 (1.00-2.00) 1.28 (1.00-2.33) 1.30 (0.86-1.89) 1.37 (0.76-2.14)
Effect size (95% CI) −0.21 (−0.63; 0.21) −0.33 (−0.76; 0.1) −0.03 (−0.46; 0.41) −0.23 (−0.68; 0.21)
M-Mode variable (mm)
IVSd 6.00 (3.30-8.40) 5.50 (3.20-7.60) 5.80 (2.90-6.90) 5.60 (4.10-8.70) 5.50 (3.60-7.40) 6.00 (3.00-8.41)
Effect size (95% CI) 0.67 (0.21; 1.14) 0.38 (−0.05; 0.81) 0.26 (−0.18; 0.71) 0.08 (−0.36; 0.52)
LVWd 6.40 (4.00-9.30) 5.70 (4.30-8.40) 6.10 (3.60-8.90) 6.70 (4.30-14.20) 6.50 (2.60-9.00) 6.3 (4.27-10.90)
Effect size (95% CI) 0.37 (−0.06; 0.81) 0.37 (−0.06; 0.81) 0.25 (−0.19; 0.7) 0.33 (−0.12; 0.78)
Doppler (m/s)
Max-LVOT 2.20 (0.70-5.10) 1.38 (0.73-4.55) 1.31 (0.57-4.84) 1.46 (0.72-5.60) 1.30 (0.70-5.20) 1.51 (0.69-5.20)
Effect size (95% CI) 0.54 (0.1; 1) 0.31 (−0.11; 0.74) 0.14 (−0.3; 0.58) −0.1 (−0.54; 0.34)
Max-RVOT 0.90 (0.00-2.60) 0.93 (0.69-1.31) 0.85 (0.66-1.99) 0.95 (0.60-2.32) 0.93 (0.49-2.24) 0.92 (0.50-2.77)
Effect size (95% CI) 0.01 (−0.4; 0.43) 0.08 (−0.33; 0.5) −0.03 (−0.47; 0.41) −0.05 (−0.49; 0.39)
Note: Data are shown for baseline and at the 6-month and 12-month recheck visits. Data are presented as median and range (minimum-maximum). There
was no significant difference between the 2 diet groups at baseline. Effect sizes (Cohen's d) between baseline and the stated timepoints are given for each
variable within each diet group; n-LVWd was analyzed as discrete (nominal) data and therefore odds ratios are shown instead. Results expressed in bold
are significant for at least 1 comparison.
Abbreviations: CI, confidence interval; IVSd, interventricular septum thickness at end-diastole; LA/Ao, ratio of the left atrial dimension to the aortic
annulus dimension; LA-max, maximum left atrial dimension; LVIDd, left ventricular internal dimension at end-diastole; LVIDs, left ventricular internal
dimension at end-systole; LVWd, left ventricular free wall thickness at end-diastole; max-IVSd, maximum interventricular septum thickness at end-diastole;
max-LVOT, maximum left ventricular outflow tract; max-LVWd, maximum left ventricular free wall thickness at end-diastole; max-RVOT, maximum right
ventricular outflow tract; NA, not available; n-(IVSd + LVWd), number of regions in which the end-diastolic interventricular septum plus the left ventricular
free wall was ≥6 mm thick; n-IVSd, number of regions in which the end-diastolic interventricular septum was ≥6 mm thick; n-LVWd, number of regions in
which the end-diastolic left ventricular free wall was ≥6 mm thick; sum-IVSd, sum of end-diastolic interventricular septum thicknesses measured in 5
separate regions; sum-LVWd, sum of end-diastolic left ventricular free wall thicknesses measured in 5 separate regions.
aComparisons between 12 months of the Test group and baseline of the Test group: P = .005 for heart rate, P = .03 for max-IVSd, P < .001 for n-IVSd,
P < .001 for sum-IVSd, and P = .02 for max-LVWd.
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multifocal hypertrophy, and were associated with the number of
hypertrophied regions in the IVS.8 Possibly therefore, inflammation
was only local with limited monocyte activation. In the study
described here, there was no significant effect of Test diet on serum
SAA. This does not exclude an effect of EPA + DHA supplementa-
tion on local inflammation and reversal of cardiac hypertrophy. We
selected SAA as a marker because our previous data showed it might
be affected by the degree of hypertrophy in sHCM, but there are a
range of other inflammatory markers that might have given positive
results in the current study.8
The effect of diet in reducing cardiac hypertrophy was much less
evident in cats with LA enlargement. In these cats, only n-IVSd and
sum-IVSd, and not maximum cardiac thickness, decreased significantly
at 12 months, while the decrease in cTnI was only significant at
6 months. Left atrial enlargement has been associated with shorter
survival in cats with HCM43 and is indicative of a more advanced
stage of sHCM close to decompensation.19 Our data suggest that
when this occurs, cardiac myocytes become less sensitive to changes
in insulin/IGF-1. This is not surprising, since at this stage a degree of
endomyocardial or interstitial fibrosis is likely to be present.20,44-46
Standard evaluation of ventricular wall thickness on echocardiog-
raphy uses the maximum measured value in any region of the IVS or
LV wall.47 The Test group had significant changes in the primary end-
points IVSd and LVWd, especially for the maximum thicknesses. Fur-
ther characterization of the cardiac effects of Test diet were provided
by less conventional evaluations, which showed that the number of
areas affected as well as the sum of thicknesses measured in these
areas decreased in the Test group.
Our study did not extend for long enough to ascertain whether
decreased LV hypertrophy resulted in better clinical outcomes,
slower disease progression or longer survival; this was beyond the
remit of the study. Presence of extreme hypertrophy (≥9 mm) is a
proven independent predictor of cardiac mortality in cats with
HCM, with similar survival times for cats with diastolic LV wall
hypertrophy between 6.0 and 8.9 mm.47 In our study, median
LVWd after 12 months of Test diet was below the diagnostic
cut-off value for ventricular hypertrophy (6 mm). Whether this
regression in wall thickness in the Test diet will influence clinical
outcome is unknown. This needs to be investigated in a longer-
term follow-up study. Interestingly, cTnI decreased significantly in
the Test group over 6 months, but not in the Control group. Circu-
lating cardiac troponins like cTnI are sensitive markers of car-
diomyocyte injury,48 and cTnI is prognostic for cardiac death in all
stages of HCM.49 Cardiac TnI concentration is reported to vary by
BW,50 but there was no difference in BW between our groups, and
no significant change in BW. We propose that the decrease in cTnI
is likely to have been caused by a decrease in cardiomyocyte
injury.
Measurements of left ventricular wall thickness decreased in cats
fed Test diet. We considered other factors such as precision of echo-
cardiographic variables and the role of medication that might have
influenced this reduction in wall thickness. The number of cats that
received medication was very small and did not differ significantly
between the Test and Control groups. Although numerically more cats
in the Control group received medication, including atenolol,
telmisartan and clopidogrel, these drugs have not been reported to
reduce left ventricular wall thicknesses or affect HCM progression in
cats with HCM.51 Bodyweight did not appear to affect the results, as
this was not different between the groups at baseline and did not
change with reductions in ventricular wall thickness. A small effect of
BW on echocardiographic measurements has been suggested in cats,
and our threshold of ≥6 mm for defining hypertrophy might have
masked a possible effect of BW, because larger cats can have larger
hearts without underlying pathology.40 It is unlikely however that
such cats would respond to a dietary intervention with decreased car-
diac hypertrophy and cardiac markers of disease. Moreover, cats with
sHCM have been reported to have cardiac marker levels significantly
higher than laboratory reference ranges and that were associated with
measures of HCM, thereby making an effect of physiological variation
in heart size in sHCM less likely.8 Systemic hypertension might result
in concentric LV hypertrophy, and this was an exclusion criterion for
this study. In cats with significant dynamic left ventricular outflow
tract obstruction, the increased afterload is a stimulus for further con-
centric left ventricular hypertrophy, and reduction in severity of
obstruction might explain regression in left ventricular wall thickness
over time. However, in this study, there was no significant change
over time in the peak LVOT or aortic velocities in either the Test diet
or Control diet groups. The presence and severity of dynamic left ven-
tricular obstruction in cats will vary with level of stress and excitement
of the patient, medications and left ventricular systolic function.
Our study had several strengths. The study had a double-blind,
prospective randomized design and included multiple centers. The
diets compared were noncommercial diets with the same nutrient
profile and minimal differences in ingredients, and were fed for
12 months. A previous study tested the hypothesis that diet could
modify clinical, biochemical or echocardiographic variables in cats with
sHCM, by feeding 6 commercial diets with varying carbohydrate, fat
and main ingredients.22 Failure to show changes in IVSd and LVWd
might have been due to small sample size (29 cats), a relative short
duration of the treatment (6 months), or excessively large differences
in nutrient profiles and ingredients between the diets. The significant
decreases in IVSd, LVWd, and cTnI in the study described here
bComparisons between 12 months of the Test group and baseline of the Control group: P = .01 for max-IVSd, P = .02 for n-IVSd and P = .009 for
sum-IVSd.
cP = .04 for the comparison of n-IVSd between 12 and 6 months of the Test group.
dP = .03 for the comparison of n-IVSd between 12 months of the Test group and 6 months of the Control group.
eP = .03 for the comparison of max-LVWd between 6 months and baseline of the Test group. P-values for were adjusted by Tukey honest significant
difference.
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suggest that the progression of sHCM in cats could possibly be
slowed by reducing levels of insulin, IGF-1, and inflammation. Even
though there were no significant differences between groups after
6 or 12 months of feeding study diets, the effect of Test diet on car-
diac measures might be regarded as significant in a targeted popula-
tion. Signalment and baseline clinical characteristics were not
different between the groups, and cats in the Test group were similar
to HCM populations previously described in terms of sex ratio,
median age, age ranging from young adult to senior, median BW and
predominant breed (domestic short-hair and long-hair breeds).43,52,53
A number of limitations in our study design and analysis might
have impacted the findings and should be considered in their interpre-
tation. None of the cats remained on the same diet that they were eat-
ing before the start of the study. We considered it preferable to make
a direct comparison between the effects of a Test diet with a matched,
study-formulated Control diet, in order to avoid potentially con-
founding factors of variable diet type, especially given prior data show-
ing no significant effect of commercial diets on wall thickness.22 Also,
in Europe, regulations required that we provided both Test and Control
cats with a diet appropriate for sHCM. Such a diet should be complete
and balanced and made from premium ingredients. Moreover it must
comply with European Commission Regulation 2020/354 on restricted
sodium levels in diets to support heart function in chronic cardiac
insufficiency.54 Due to this limitation in study design, we cannot
exclude the possibility of a difference between the Test and Control
groups had the Control cats remained on the diets they were fed
before study start. Nevertheless, although there are few serial data on
changes in wall measurements over time in cats with sHCM, reduction
in left ventricular wall thickness is not an expected outcome. There-
fore, we might assume that if cats in the Control group had remained
on their prestudy diets, they would have continued to show disease
progression, but we cannot prove this. In controlled pharmacologic
studies evaluating the effect of angiotensin converting enzyme inhibi-
tors there are no changes in ventricular hypertrophy in cats receiving
standard therapy.55,56 Conversely, end-stage HCM in some cats might
be associated with LV chamber dilatation, systolic dysfunction, and rel-
ative thinning of the LV walls,57-59 but these changes are evident over
years. Another condition which might result in resolution of left ven-
tricular hypertrophy is transient myocardial thickening (TMT), which
has shown fast reverse remodeling in a median of 3.3 months after
antecedent events in cats that were significantly younger than HCM
controls (median 1.7 years vs 8 years, respectively). The age, history
F IGURE 2 Box and whisker plots for the change (delta) in echocardiography variables from baseline to 6-month (clear boxes) and 12-month
(shaded boxes) evaluations in cats with subclinical hypertrophic cardiomyopathy fed Test (n = 23) or Control diet (n = 21) for a total of 12 months.
The horizontal bars represent the median values and the crosses the mean values. Whiskers show the range of values that are up to 1.5 times
larger than the third quartile or 1.5 times lower than the first quartile. Circles are outliers outside of these ranges. A, Change in max-IVSd (mm). B,
Change in max-LVFWd (mm). C, Change in IGF-1 (ng/mL). D, Change in log-transformed cTnI (ng/mL) (log-transformed in order to fulfill model
assumptions of normally distributed residuals and homoscedasticity). The circle for the Control diet in plot D is 2 superimposed outliers with
values indistinguishable on the scale presented. cTnI, cardiac troponin I; IGF-1, insulin-like growth factor-1; IVSd, interventricular septum
thickness at end-diastole; LVFWd, left ventricular free wall thickness at end-diastole
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and time-course of the echocardiographic changes of the cats in this
study are not consistent with TMT.
Diet history was not recorded at enrollment. Both Test and Con-
trol diets were complete and balanced with restricted sodium levels
and premium ingredients. It is possible that switching to a diet of bet-
ter quality and a different sodium level in the study caused the
changes observed in cardiac variables and resulted in our inability to
detect differences between diets.
The inclusion criterion for systolic blood pressure <180 mm Hg
was higher than currently recommended60 and it is possible that some
borderline hypertensive or mildly hypertensive cats were included,
but at low risk for target organ damage.60 We selected a higher cut-
off to allow for situational (stress-associated) hypertension in some
cats. The population median blood pressure was normal at
130 mm Hg, so systemic hypertension is unlikely to have been a sig-
nificant confounding factor in the study groups.
TABLE 5 Statistical significance and effect sizes for changes over time in echocardiographic measurements and cardiac troponin I in cats with
subclinical hypertrophic cardiomyopathy with or without left atrial enlargement at baseline
Variable
Cats without LA enlargement at baseline (n = 21) Cats with LA enlargement at baseline (n = 23)
Effect of
time P
value
Test group decrease
between baseline and
12 months
Control group decrease
between baseline and
12 months
Effect of
time P
value
Test group decrease
between baseline and
12 months
Control group decrease
between baseline and
12 months
Max-IVSd
P value .005 .06 .38 .38 .69 1
Effect size (95% CI) 0.92 (0.2; 1.69) 0.58 (−0.11; 1.31) 0.31 (−0.29; 0.92) 0.16 (−0.46; 0.78)
n-IVSd
P value .01 .04 .76 .005 .02 .81
Effect size (95% CI) 1.16 (0.38; 2.01) 0.39 (−0.28; 1.08) 0.66 (0.02; 1.34) 0.54 (−0.11; 1.22)
Sum-IVSd
P value .003 .02 .43 .004 .03 .37
Effect size (95% CI) 1.04 (0.3; 1.86) 0.54 (−0.15; 1.26) 0.72 (0.07; 1.4) 0.61 (−0.05; 1.3)
Max-LVWd
P value .02 .05 .1 .15 .56 .94
Effect size (95% CI) 0.74 (0.06; 1.47) 0.36 (−0.3; 1.05) 0.5 (−0.12; 1.14) 0.22 (−0.41; 0.85)
Sum-LVWd
P value .05 .11 .99 .19 .67 .98
Effect size (95% CI) 0.59 (−0.07; 1.28) 0.41 (−0.26; 1.1) 0.46 (−0.15; 1.09) 0.17 (−0.45; 0.8)
n-(IVSd + LVWd)
P value .02 .06 .82 .04 .15 .83
Effect size (95% CI) 0.84 (0.14; 1.59) 0.36 (−0.3; 1.05) 0.55 (−0.07; 1.2) 0.38 (−0.25; 1.03)
LA-max
P value .003 .01 .74 .63 1 1
Effect size (95% CI) −1.06 (−1.88; −0.31) −0.59 (−1.32; 0.1) −0.22 (−0.82; 0.38) −0.29 (−0.93; 0.34)
Max-LVOT
P value .95 1 1 .02 .28 .98
Effect size (95% CI) 0.08 (−0.54; 0.7) 0.02 (−0.63; 0.68) 0.5 (−0.12; 1.14) −0.17 (−0.8; 0.45)
Max-RVOT
P value .54 .72 1 .01 .79 .38
Effect size (95% CI) 0.13 (−0.49; 0.76) −0.19 (−0.85; 0.47) 0.05 (−0.54; 0.64) 0.12 (−0.5; 0.74)
HR
P value .006 .008 .9 .92 .58 .69
Effect size (95% CI) 0.89 (0.14; 1.7) 0.48 (−0.2; 1.18) 0.44 (−0.17; 1.07) 0.08 (−0.54; 0.71)
cTnI
P value .03 .91 .99 .04 .18 .92
Effect size (95% CI) 0.27 (−0.36; 0.91) −0.03 (−0.68; 0.63) 0.41 (−0.2; 1.03) −0.36 (−1.01; 0.27)
Note: Statistical analysis was by linear mixed models (2-way repeated measures ANOVA with the measured variables compared with both time and diet
group) for continuous variables and generalized linear mixed models for nominal variables. Time, diet and the interaction between them were defined as
fixed effects; cat was a random term. Statistical significance was set at P < .05 for 2-sided analyses. P-values for comparisons in variables between baseline
and 12 months were adjusted by Tukey honest significant difference. Effect sizes (Cohen's d) between baseline and the stated timepoint are given for each
variable within each diet group.
Abbreviations: CI, confidence interval; cTnI, cardiac troponin I; HR, heart rate; LA-max, maximum left atrial dimension; max-LVOT, maximum left
ventricular outflow tract; max-IVSd, maximum interventricular septum thickness at end-diastole; max-RVOT, maximum right ventricular outflow tract; M-
IVSd, M-mode left ventricular thickness at end-diastole; n-(IVSd + LVWd), number of regions in which the end-diastolic interventricular septum plus the
left ventricular free wall was ≥6 mm; n-IVSd, number of regions in which the end-diastolic interventricular septum was ≥6 mm; sum-IVSd, sum of end-
diastolic interventricular septum thicknesses measured in 5 separate regions; sum-LVWd, sum of end-diastolic left ventricular free wall thicknesses
measured in 5 separate regions.
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Prevalence of murmur in the Test group (100%) was higher than
previously described because it was 1 of the key identifiers for the
referred population in cats with sHCM.43,53 In addition, 1 center
actively recruited cats with cardiac murmurs. Heart murmurs were
associated with dynamic LV outflow tract obstruction (DLVOTO),
often termed hypertrophic obstructive cardiomyopathy (HOCM).
Other studies have shown that cats with DLVOTO have a favorable
prognosis compared to cats with clinical signs of HCM, as the disease
is detected at an earlier stage.61 Such earlier diagnosis might have
contributed to the response to Test diet, as discussed above for cats
without or with LA enlargement.
Some of the echocardiographic evaluations in this study have not
been validated in cats but were used to enrich our understanding of
the data. By assessing the number of areas ≥6 mm we aimed to detect
diet effects that might occur in some areas without changing the over-
all maximum thickness. Additionally, changes in the sum of thick-
nesses in the evaluated regions would incorporate any diet effects on
areas ≤6 mm. Interobserver variability could potentially have
influenced the results, although the echocardiology measures used
are common, and changes observed in max-IVSd and max-LVWd were
larger than 5.9%, which was the highest interobserver CV for the pri-
mary endpoints. This CV is comparable to the overall interobserver
CV for repeated measurements of echocardiography previously
described in healthy cats.62
In summary, no differences between diet groups were significant
for any variable at any timepoint. Cats fed a diet restricted in starch and
supplemented with omega-3 fatty acids showed remodeling of the IVS
and LVFW and decreased levels of cardiac marker cTnI, with changes
being less evident in cats with LA enlargement. For the first time it was
shown that diet could influence echocardiographic variables in cats with
sHCM. This supports our hypothesis that manipulation of the levels of
key dietary constituents might influence cardiomyocyte hypertrophy
and thickness of the LV wall in cats with sHCM.
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